Berotralstat Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 150 mg,110 mg
Reference Brands: Orladeyo (USA)
Category:
Immune Disorder
Berotralstat Hydrochloride is available in Tablets
and strengths such as 150 mg,110 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Berotralstat Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Berotralstat Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Berotralstat, marketed under the brand name Orladeyo, is an oral plasma kallikrein inhibitor used for the prophylactic treatment of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. HAE is a rare genetic disorder characterized by recurrent episodes of severe swelling in various parts of the body, including the face, extremities, gastrointestinal tract, and airway. These attacks can be painful, debilitating, and potentially life-threatening when the airway is involved.
By selectively inhibiting plasma kallikrein, berotralstat reduces the excessive production of bradykinin, a key mediator responsible for the swelling and pain experienced during HAE attacks. This mechanism helps prevent the onset of HAE episodes, improving patient quality of life and providing a convenient, once-daily oral therapy compared to injectable alternatives. Berotralstat represents a targeted approach for long-term disease management, offering patients effective prophylaxis against recurrent hereditary angioedema attacks.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing